期刊
NEUROLOGY
卷 78, 期 17, 页码 1337-1345出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3182535d20
关键词
-
资金
- American Academy of Neurology
- American Headache Society
- AGA
- Allergan
- Boston Scientific
- Capnia
- Coherex
- Endo Pharmaceuticals
- GlaxoSmithKline
- Lilly
- MAP
- Medtronic
- Merck
- NINDS
- NuPathe
- St. Jude Medical
- Valeant Pharmaceuticals
- Albert Einstein College of Medicine
- Wolff's Headache
- Advanced Neurostimulation Systems
- St Jude Medical, Inc.
- NINDS/NIH
- Mayo Clinic
- Forest Laboratories
- Eli Lilly
- Neurogesx
- Pfizer
- NIH
Objective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention? Methods: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention. Results and Recommendations: The author panel reviewed 284 abstracts, which ultimately yielded 29 Class I or Class II articles that are reviewed herein. Divalproex sodium, sodium valproate, topiramate, metoprolol, propranolol, and timolol are effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity (Level A). Frovatriptan is effective for prevention of menstrual migraine (Level A). Lamotrigine is ineffective for migraine prevention (Level A). Neurology (R) 2012; 78: 1337-1345
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据